DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors

Summary

The goal of this clinical trial is to test the efficacy of induction treatment of immunotherapy and chemotherapy depending on the resection status for the treatment of non small cell lung cancer patients diagnosed with pancoast tumor. The main objectives it aims to answer are: * Complete resection rate after induction treatment with chemotherapy plus nivolumab * Overall Survival and Progression Free Survival at 24 months The sample size is 40 patients.

Timeline

Start

2023-05-12

Primary completion

2028-03-01

Completion

2028-06-01

Drugs

Indications